MONMOUTH JUNCTION, N.J., Sept. 29, 2016 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) a critical care immunotherapy company working to save lives through blood purification, announced the launch of its newly redesigned corporate website, CytoSorbents.com. The new site highlights CytoSorbents' rapid international growth and leadership in treating deadly inflammation in critical illnesses and cardiac surgery with its flagship product, CytoSorb®, and reflects the broad new growth opportunities of its expanding and innovative product pipeline.
Visitors to the new site will find a wealth of new and streamlined information on CytoSorbents' pioneering blood purification technology and how it is being adapted to address many of most pressing unmet medical needs. Physicians, patients, customers, journalists, and potential partners will receive a complete overview of CytoSorb® and its role in helping to save lives, before being redirected to the official CytoSorb product website where an even greater level of detail awaits. Investors will find key technical and financial information about the company, updates on its world-class strategic partners, summaries of clinical data, archived presentations and multimedia, the ability to join the company's email news list, a quick link to the company's Facebook, Twitter, and LinkedIn pages, and more.
"Our new website is designed to provide a comprehensive, up-to-date snapshot of our Company, offering an informative, user-friendly, and easy-to-navigate experience to all of our global stakeholders," stated Dr. Phillip Chan, Chief Executive Officer of CytoSorbents. "We are passionate about the ground-breaking work that we do and with this revitalized online presence, we look to spread our message far and wide, with the goal of ensuring that people know about our Company, our products, and our technology to help those in greatest need, wherever they may be."
Visit CytoSorbents.com to learn more.
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 39 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. CytoSorbents is in the process of completing its REFRESH (REduction in FREe Hemoglobin) 1 trial - a multi-center, randomized controlled study evaluating the safety of intra-operative CytoSorb® use in a heart-lung machine during complex cardiac surgery. In early 2017, the company plans to initiate a pivotal REFRESH 2 trial intended to support U.S. FDA approval. CytoSorb® has been used safely in more than 14,000 human treatments to date.
CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant and contract funding in excess of $18 million from DARPA, the U.S. Army, the U.S. Air Force, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM) and others. The Company has numerous products under development based upon this unique blood purification technology, protected by 32 issued U.S. patents and multiple applications pending, including CytoSorb-XL, HemoDefend™, ContrastSorb, DrugSorb and others. For more information, please visit the Company's websites: http://www.cytosorbents.com and http://www.cytosorb.com or follow us on Facebook and Twitter.
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 9, 2016, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
(732) 329-8885 ext. *825
Public Relations Contact:
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-cytosorbents-website-highlights-global-growth-and-innovation-300336459.html
SOURCE CytoSorbents Corporation